Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

VYNE Therapeutics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPANY IS PROGRESSING ITS PREVIOUSLY INITIATED STRATEGIC REVIEW EVALUATING A RANGE OF OPTIONS TO MAXIMIZE SHAREHOLDER VALUE, INCLUDING ASSESSMENT OF INTERNAL PIPELINE OPPORTUNITIES AND BROADER STRATEGIC ALTERNATIVES 12-WEEK, NON-CLINICAL TOXICOLOGY STUDY OF VYN202 IN DOGS TO REMEDY THE PARTIAL HOLD IN MALE CLINICAL SUBJECTS IS ONGOING; COMPANY CONTINUES TO EVALUATE POTENTIAL OPPORTUNITIES FOR VYN202 AS A TREATMENT FOR SERIOUS, IMMUNE-MEDIATED DISEASES CASH RUNWAY INTO FIRST HALF OF 2027 BASED ON PREVIOUSLY ANNOUNCED COST REDUCTIONS BRIDGEWATER, N.J., NOV. 06, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY REPORTED FINANCIAL RESULTS AS OF AND FOR THE QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE.

VYNE Therapeutics Inc.

VYNE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VYNE Therapeutics Inc.

VYNE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VYNE